Apellis Pharmaceuticals (APLS) PT Raised to $115 at Baird, 'Survey data bode well for the ongoing launch of Syfovre'

KOL thinks Apellis Pharmaceuticals (APLS) issues with Syfovre 'likely solvable' - TD Cowen

TD Cowen analyst Phil Nadeau weighed in on Apellis Pharmaceuticals (NASDAQ: APLS) after shares fell 38% after six cases of retinal vasculitis have been reported with Syfovre.

The analyst commented, "During TD Cowen Rounds @ Cleveland Clinic today we discussed the situation with a... More

Stifel on Apellis Pharmaceuticals (APLS): 'we expect this pressure to be short-lived'

Stifel analyst Annabel Samimy reiterated a Buy rating and $90.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "

The recent ASRS member notification has stoked new safety fears for Syfovre, with notification of six IOI events with retinal vasculitis, calculated... More

Citi Keeps Buy Rating on Apellis Pharmaceuticals (APLS), Comments on Premarket Selloff

Citi analyst Yigal Nochomovitz reiterated a Buy rating and $106.00 price target on Apellis Pharmaceuticals (NASDAQ: APLS)

The analyst comments "The stock is down substantially this AM following an ASRS member notification yesterday regarding a small number of events of intraocular inflammation (IOI, exact number... More

Evercore ISI Remains Positive on Apellis Pharmaceuticals (APLS)

Evercore ISI analyst Umer Raffat reiterated an Outperform rating on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "Facts: 6 cases of occlusive retinal vasculitis. 7-13 days post-drug. Outcomes evolving. - APLS mentions that there is not consensus on 6 cases (KOLs on our call agree). This ASRS update is NOT peer-reviewed - Also, 1/6 patient has significant vision loss outcomes on other may not be as significant But regardless, one thing is clear: such cases had not been in clinical trials previously. Perhaps thats the first distinction vs Novartis Beovu: There were cases of retinal artery... More

Apellis Pharmaceuticals (APLS) plunges as occlusive retinal vasculitis observed from Syfovre launch

Apellis Pharmaceuticals (NASDAQ: APLS) witnessed a dramatic decline of approximately 40% in pre-market trading on Monday. This decline followed the distribution of a notification by the ASRS Research and Safety in Therapeutics (ReST) Committee to its members over the weekend. The notification provided key information including the observation of six cases of occlusive retinal vasculitis since the launch of Syfovre, according to Raymond James analysts. Importantly, all these events occurred after the first injection, within a time frame of 7 to 13 days post-injection, with no specific product lots implicated. Meanwhile, over... More

Raymond James Comments on Apellis Pharmaceuticals (APLS) Amid Stock Selloff in Premarket

Raymond James analyst Steven Seedhouse reiterated a Strong Buy rating and price target on Apellis Pharmaceuticals (NASDAQ: APLS).

The analyst comments "The ASRS Research and Safety in Therapeutics (ReST) Committee distributed a notification to its members on Saturday (7/15) indicating 1) 6 cases of occlusive retinal vasculitis have been observed since Syfovre launch, 2) all events observed after 1st injection, between 7-13 days post injection, 3) no specific product lots implicated. Moreover, the communication indicates ~60,000 vials of Syfovre have been distributed since FDA approval. We spoke with Apellis who confirmed the details. We highlight relevant occlusive retinal... More